Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Axsome Therapeutics’ disclosures can feel like decoding clinical jargon when all you want to know is whether a pivotal trial met its endpoint or if insiders are buying shares ahead of FDA feedback. Our SEC filings hub starts where the dense language ends—delivering Axsome Therapeutics SEC filings explained simply so you can move from page 200 straight to the insight.
Stock Titan’s AI reads every submission the moment it hits EDGAR and surfaces what professionals track most: cash-runway details from the Axsome Therapeutics annual report 10-K simplified, enrollment updates buried in an Axsome Therapeutics quarterly earnings report 10-Q filing, or trial-stopping events disclosed through an Axsome Therapeutics 8-K material events explained. You’ll also receive real-time alerts for Axsome Therapeutics Form 4 insider transactions real-time—critical when evaluating management’s conviction.
Whether you’re scanning an Axsome Therapeutics proxy statement executive compensation to see how milestone bonuses align with R&D progress, or conducting an Axsome Therapeutics earnings report filing analysis to compare R&D spend quarter over quarter, our platform translates complexity into clarity. Expect:
- Concise AI-powered summaries that highlight trial milestones, safety signals, and liquidity trends
- Immediate access to every filing type, including Axsome Therapeutics insider trading Form 4 transactions
- Keyword search across thousands of pages for faster due diligence
Stop downloading PDFs. Start understanding Axsome Therapeutics SEC documents with AI—from executive stock transactions Form 4 to breakthrough therapy designations—without wading through biotech terminology.
Form 144 notice for Axsome Therapeutics, Inc. (AXSM) records a proposed sale of 16,694 common shares through Charles Schwab & Co., Inc. on 08/22/2025 on NASDAQ with an aggregate market value of $2,004,598. The filing reports total shares outstanding of 49,901,487. The securities to be sold were acquired by exercise and hold on 09/16/2014 (3,672 shares), 11/19/2015 (9,127 shares) and 05/27/2016 (3,895 shares), each paid in cash. The form states there were no securities sold in the past three months for the account. Several header fields identifying the filer and issuer appear blank in the provided content.
RTW Investments, LP and Roderick Wong disclose a 3.1% stake in Axsome Therapeutics. The filing reports ownership of 1,516,903 shares, calculated from 49,236,365 shares outstanding as of April 28, 2025. The shares are held directly by RTW Funds, for which RTW Investments acts as investment adviser, and Dr. Wong is identified as Managing Partner and Chief Investment Officer with shared voting and dispositive power over the reported position. The statement affirms the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Because the position is below 5%, it does not cross the threshold that typically requires more detailed disclosure of control intentions.
Axsome Therapeutics’ Q2-25 10-Q shows fast topline growth, narrower losses and a refinancing that reshapes the balance sheet.
- Revenue: Q2 product sales surged 72 % YoY to $148.9 M (Sunosi, Auvelity, launch-quarter Symbravo) lifting total revenue to $150.0 M. 1H-25 revenue rose 67 % to $271.5 M.
- Profitability: Q2 operating loss narrowed to $36.7 M vs. $78.0 M; net loss improved to $48.0 M (-$0.97/sh) from $79.3 M (-$1.67/sh). 1H net loss was $107.4 M. Gross margin remained high (cost of product 9 % of sales).
- Expenses: SG&A climbed 26 % YoY to $130.3 M (marketing for three brands); R&D essentially flat at $49.5 M. Advertising spend YTD $63.7 M.
- Cash & liquidity: Cash/cash equivalents $303.0 M (-$12.3 M YTD). Operating cash burn $75.8 M, improved vs. $83.6 M prior year.
- Capital structure: May 2025 Blackstone facility (up to $570 M) replaced Hercules debt. At 6-30-25: $120 M term loan (9.6 % SOFR+4.75%) and $70 M revolver (SOFR+4.0%) drawn; long-term debt net of discount $117.5 M (down from $180.7 M). Loss on extinguishment $10.4 M recorded.
- Equity: Shares outstanding 49.9 M (+2 % YTD). Stockholders’ equity up to $73.1 M from $57.0 M.
- Outlook: Management believes current cash covers operations ≥12 months while commercialization spending rises for Auvelity, Sunosi and newly launched Symbravo.
Key takeaways: Rapid revenue expansion and refinancing reduce financing risk, but sustained operating losses, heavy SG&A and rising receivables remain watch points.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed multiple stock option exercises and sales under a pre-approved 10b5-1 plan:
- On June 20, 2025: Exercised 7,500 stock options at $29.91 and immediately sold the shares at an average price of $102.47, realizing approximately $544,200 in gross proceeds
- On June 23, 2025: Exercised 6,014 stock options at $29.91 and sold at an average price of $100.12, generating approximately $421,700 in gross proceeds
Following these transactions, Murdock retains 16,369 stock options exercisable until March 4, 2032. The trades were executed through a completed 10b5-1 trading plan, which provides a safe harbor from insider trading allegations by pre-scheduling trades. The significant spread between exercise price ($29.91) and sale prices ($100-103) indicates substantial share price appreciation since the option grant date.
Form 144 Notice Filing for Axsome Therapeutics (NASDAQ: AXSM) details proposed sale of securities by insider Hunter R. Murdock. The filing indicates a planned sale of 6,014 shares of common stock with an aggregate market value of $602,101, to be executed through Charles Schwab & Co.
The shares were acquired through an Employee Stock Option Exercise on June 23, 2025, with payment made via a cashless exercise through broker. The filing reveals significant recent insider trading activity by the same individual over the past three months:
- June 20, 2025: 7,500 shares sold for $768,503
- June 18, 2025: 7,500 shares sold for $756,729
- June 17, 2025: 7,500 shares sold for $751,975
- June 16, 2025: 7,500 shares sold for $768,154
Total outstanding shares reported: 49,236,365. The proposed sale represents a continuation of systematic insider selling pattern, with approximately 30,000 shares sold in the preceding month.
Form 144 Notice filed by Axsome Therapeutics (NASDAQ: AXSM) on June 28, 2025, detailing proposed securities sales under Rule 144. The filing indicates planned sale of 7,500 shares of common stock with an aggregate market value of $768,503 through Charles Schwab & Co.
Key transaction details:
- Securities acquired through employee stock option exercise on June 20, 2025
- Payment made via broker payment for cashless exercise
- Total shares outstanding: 49,236,365
- Planned sale date: June 20, 2025
The filing also discloses previous sales by Hunter R. Murdock in the past 3 months totaling 22,500 shares across three transactions from June 16-18, 2025, with gross proceeds ranging from $751,975 to $768,154. The seller represents no knowledge of undisclosed material adverse information regarding the issuer.
Hunter R. Murdock, General Counsel of Axsome Therapeutics (AXSM), executed a series of pre-planned transactions under a 10b5-1 trading plan over three consecutive days from June 16-18, 2025.
The transactions followed a consistent pattern each day:
- Exercised 7,500 stock options at $29.91 per share
- Immediately sold 7,500 shares at weighted average prices between $100.26-$102.42
Total transaction summary:
- Exercised: 22,500 options
- Sold: 22,500 shares
- Remaining options: 29,883
- Net proceeds per share: approximately $70-72 (sale price minus exercise price)
These transactions were executed according to a pre-approved trading plan, which helps protect executives from insider trading allegations by establishing trade parameters in advance.
FAQ
What is the current stock price of Axsome Therapeut (AXSM)?
What is the market cap of Axsome Therapeut (AXSM)?
